CATALOGO DEI PRODOTTI DELLA RICERCA

PILOTTO, Sara
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 9.050
NA - Nord America 8.837
AS - Asia 6.770
SA - Sud America 990
AF - Africa 255
OC - Oceania 17
Continente sconosciuto - Info sul continente non disponibili 6
AN - Antartide 1
Totale 25.926
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.604
RU - Federazione Russa 4.143
SG - Singapore 2.783
CN - Cina 1.775
GB - Regno Unito 1.198
IT - Italia 1.002
BR - Brasile 763
VN - Vietnam 693
HK - Hong Kong 619
DE - Germania 586
SE - Svezia 457
FR - Francia 419
IE - Irlanda 380
FI - Finlandia 316
KR - Corea 234
IN - India 146
NL - Olanda 134
CA - Canada 116
PL - Polonia 93
AR - Argentina 80
JP - Giappone 80
ID - Indonesia 74
BD - Bangladesh 62
UA - Ucraina 62
MX - Messico 61
ES - Italia 54
TR - Turchia 48
ZA - Sudafrica 45
TG - Togo 42
NG - Nigeria 41
AT - Austria 40
IQ - Iraq 38
BJ - Benin 37
EC - Ecuador 31
BE - Belgio 29
CO - Colombia 28
VE - Venezuela 28
PK - Pakistan 26
CZ - Repubblica Ceca 24
MA - Marocco 24
CL - Cile 23
LT - Lituania 17
PH - Filippine 17
UZ - Uzbekistan 17
AU - Australia 15
CH - Svizzera 15
IR - Iran 15
AE - Emirati Arabi Uniti 13
SA - Arabia Saudita 13
TN - Tunisia 13
JO - Giordania 12
KZ - Kazakistan 12
PE - Perù 12
EG - Egitto 11
PY - Paraguay 11
CR - Costa Rica 10
KE - Kenya 10
NP - Nepal 10
HN - Honduras 9
MY - Malesia 9
AZ - Azerbaigian 8
LV - Lettonia 8
AM - Armenia 7
BO - Bolivia 7
CY - Cipro 7
DK - Danimarca 7
DZ - Algeria 7
GR - Grecia 7
IL - Israele 7
JM - Giamaica 7
KG - Kirghizistan 7
RO - Romania 7
AL - Albania 6
NO - Norvegia 6
PT - Portogallo 6
UY - Uruguay 6
DO - Repubblica Dominicana 5
EU - Europa 5
PA - Panama 5
RS - Serbia 5
SK - Slovacchia (Repubblica Slovacca) 5
SN - Senegal 5
SV - El Salvador 5
AO - Angola 4
HR - Croazia 4
KH - Cambogia 4
LA - Repubblica Popolare Democratica del Laos 4
LK - Sri Lanka 4
NI - Nicaragua 4
PS - Palestinian Territory 4
SI - Slovenia 4
SY - Repubblica araba siriana 4
TW - Taiwan 4
BG - Bulgaria 3
GA - Gabon 3
HU - Ungheria 3
OM - Oman 3
BH - Bahrain 2
BM - Bermuda 2
BS - Bahamas 2
Totale 25.882
Salva come PNG Salva come JPEG
Città #
Singapore 1.445
Moscow 1.403
Ashburn 1.283
San Jose 1.019
Dallas 1.000
Southend 901
Chandler 819
Hong Kong 607
Verona 394
Dublin 377
Beijing 360
The Dalles 313
Woodbridge 298
Munich 269
New York 221
Ho Chi Minh City 220
Los Angeles 216
Jacksonville 198
Ann Arbor 181
Hanoi 156
Council Bluffs 128
Lawrence 125
Princeton 125
Helsinki 121
Wilmington 114
Jinan 105
São Paulo 92
London 90
Houston 86
Buffalo 79
Santa Clara 76
Redondo Beach 75
Tokyo 73
Turku 72
Milan 70
Tianjin 70
Sindelfingen 64
Shenyang 60
Redmond 59
Orem 57
Meda 55
Nanjing 54
Seoul 53
Amsterdam 51
Frankfurt am Main 51
Columbus 50
Hebei 50
Warsaw 50
Montreal 45
Seattle 44
Lomé 42
Lappeenranta 40
Abuja 39
Guangzhou 39
Brooklyn 38
Chicago 38
Jakarta 38
Cotonou 37
Rome 36
Washington 36
Chennai 35
Atlanta 34
Stockholm 34
Nanchang 33
Da Nang 32
Zhengzhou 32
Denver 31
Hangzhou 31
Johannesburg 31
Kent 31
San Francisco 31
Boardman 30
Nuremberg 30
Brussels 29
Changsha 29
Haikou 29
Haiphong 27
Ningbo 27
Toronto 27
Phoenix 26
Rio de Janeiro 24
Baghdad 23
Belo Horizonte 23
Dong Ket 22
Vienna 22
Bologna 21
Mexico City 21
Mumbai 21
Biên Hòa 20
Boston 20
Paris 20
Poplar 20
Taiyuan 20
Taizhou 20
Barnet 19
City of London 19
Manchester 19
Falls Church 18
Shanghai 18
Curitiba 17
Totale 15.323
Salva come PNG Salva come JPEG
Nome #
Immune checkpoint blockade therapy mitigates systemic inflammation and affects cellular FLIP-expressing monocytic myeloid-derived suppressor cells in non-progressor non-small cell lung cancer patients 307
Comprehensive molecular portrait using next generation sequencing of resected intestinal-type gastric cancer patients dichotomized according to prognosis 253
"Running with cancer": A qualitative study to evaluate barriers and motivations in running for female oncological patients 248
ALK gene copy number in lung cancer: Unspecific polyploidy versus specific amplification visible as double minutes 247
ALK/EML4 Fusion Gene May Be Found in Pure Squamous Carcinoma of the Lung 239
High-throughput mutation profiling identifies novel molecular dysregulation in high-grade intraepithelial neoplasia and early gastric cancers 225
ALK gene copy number gains in non-small-cell lung cancer: prognostic impact and clinico-pathological correlations 215
An overview of angiogenesis inhibitors in Phase II studies for non-small-cell lung cancer 212
Prognostic impact of proliferation for resected early stage 'pure' invasive lobular breast cancer: Cut-off analysis of Ki67 according to histology and clinical validation 207
Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers 200
Next-generation repeat-free FISH probes for DNA amplification in glioblastoma in vivo: Improving patient selection to MDM2-targeted inhibitors 200
Deep vein thrombosis in SARS-CoV-2 pneumonia-affected patients within standard care units: Exploring a submerged portion of the iceberg 198
Impact of neoadjuvant single or dual HER2 inhibition and chemotherapy backbone upon pathological complete response in operable and locally advanced breast cancer: Sensitivity analysis of randomized trials 196
Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of Ki67 assay according to histology: prognostic relevance for resected early stage 'pure' and 'mixed' lobular breast cancer 196
Adjuvant Chemotherapy For Resected Non-Small-Cell Lung Cancer: Future Perspectives For Clinical Research 194
Current and developing therapies for the treatment of non-small cell lung cancer with ALK abnormalities: update and perspectives for clinical practice 187
Organisational challenges, volumes of oncological activity and patients' perception during the severe acute respiratory syndrome coronavirus 2 epidemic 187
A Feasibility Study Investigating an Exercise Program in Metastatic Cancer Based on the Patient-Preferred Delivery Mode 185
Addressing the expected survival benefit for clinical trial design in metastatic castration-resistant prostate cancer: Sensitivity analysis of randomized trials 185
A multimodal approach to cancer-related cachexia: from theory to practice 185
Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma 179
The coming of ramucirumab in the landscape of anti-angiogenic drugs: potential clinical and translational perspectives 179
Neoadjuvant strategies for triple negative breast cancer: 'state-of-the-art' and future perspectives 177
Gene expression profiling of lung atypical carcinoids and large cell neuroendocrine carcinomas identifies three transcriptomic subtypes with specific genomic alterations 177
Advances towards the design and development of personalized non-small-cell lung cancer drug therapy. 175
Exercise prehabilitation in lung cancer: Getting stronger to recover faster 175
A cross-sectional study evaluating the exercise discussion with oncologist during cancer consultation: the CONNECT study 174
Adjuvant therapy for resected early-stage small-cell lung cancer: is now time to rethink about that? 174
Abscopal effect and resistance reversion in nivolumab-treated non-small-cell lung cancer undergoing palliative radiotherapy: a case report 174
A propensity score analysis exploring the impact of adjuvant chemotherapy (aCT) in a multi-center series of resected early stage pure invasive lobular breast carcinoma (ILC) 173
Preliminary results of PRINCiPe (predictors of resistance to immunotherapy with nivolumab [NIV]) study in advanced pretreated non-small cell lung cancer (APNSCLC), investigating the role of an immune genomic signature (IGS) including JAK2, JAK3, PIAS4, PTPN2, STAT3, IFNAR2 alterations 172
Lung neuroendocrine tumours: deep sequencing of the four WHO histotypes reveals chromatin remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D 171
Tubulin inhibitors in non-small cell lung cancer: looking back and forward 169
Prognostic Impact of Preoperative Nutritional Risk in Patients Who Undergo Surgery for Pancreatic Adenocarcinoma 168
Development of Educational Print Materials for Physical Activity in Cancer: Evaluation of Readability and Suitability 165
Predictive and Prognostic Role of Tumor-Infiltrating Lymphocytes for Early Breast Cancer According to Disease Subtypes: Sensitivity Analysis of Randomized Trials in Adjuvant and Neoadjuvant Setting 164
Clinical implication of changes in body composition and weight in patients with early-stage and metastatic breast cancer 164
Do immune checkpoint inhibitors need new studies methodology? 163
A narrative review on tumor microenvironment in oligometastatic and oligoprogressive non-small cell lung cancer: a lot remains to be done 162
Integrating supportive care into the multidisciplinary management of lung cancer: we can't wait any longer 162
Clinical results of randomized trials and 'real-world' data exploring the impact of Bevacizumab for breast cancer: opportunities for clinical practice and perspectives for research 161
Exercise levels and preferences in cancer patients: a cross-sectional study 161
How the COVID-19 Pandemic Impacted on Integrated Care Pathways for Lung Cancer: The Parallel Experience of a COVID-Spared and a COVID-Dedicated Center 161
Prognostic model for advanced breast carcinoma with luminal subtype and impact of hormonal maintenance: Implications for post-progression and conditional survival 160
Characterization of Myeloid-derived Suppressor Cells in a Patient With Lung Adenocarcinoma Undergoing Durvalumab Treatment: A Case Report 159
Risk Stratification Model for Resected Squamous-Cell Lung Cancer Patients According to Clinical and Pathological Factors 157
MET exon 14 juxtamembrane splicing mutations: clinical and therapeutical perspectives for cancer therapy 157
Psychological impact of Covid-19 pandemic on oncological patients: a survey in Northern Italy 157
Anticipating EGFR Targeting in Early Stages of Lung Cancer: Leave No Stone Unturned 157
A qualitative study exploring the experiences and perspectives of patients with cancer attending a 12-week exercise program 156
Surface CD52, CD84, and PTGER2 mark mature PMN-MDSCs from cancer patients and G-CSF-treated donors 156
Evaluation of nutritional status in non-small-cell lung cancer: screening, assessment and correlation with treatment outcome 155
Anti-Angiogenic Drugs and Biomarkers in Non-Small-Cell Lung Cancer: A 'Hard Days Night' 154
Infections and Immunotherapy in Lung Cancer: A Bad Relationship? 154
Antibody-drug conjugates (ADCs) targeting TROP-2 in lung cancer 151
Exercise for counteracting post-acute COVID-19 syndrome in patients with cancer: an old but gold strategy? 151
Characterizing the immune tumor microenvironment in ALK fusion-positive lung cancer: state-of-the-art and therapeutical implications 150
A cross-sectional study exploring the perception of exercise oncology in the Italian population 150
Putative predictors of efficacy for immune checkpoint inhibitors in non-small-cell lung cancer: facing the complexity of the immune system. 150
Maintenance or consolidation therapy in small-cell lung cancer: an updated systematic review and meta-analysis 149
Multidisciplinary lifestyle intervention to manage pancreatic cancer-related cachexia: a case report 149
Potential role of RICTOR copy number gain (CNG) as a key biomarker of mTOR activity: A comprehensive preclinical analysis in squamous cell lung cancer (SQLC) models 148
ARID1A mutational status in non-small cell lung cancer: from molecular pathology to clinical implications with a focus on the relationships with EGFR 146
Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer 145
Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study 145
Muscle derangement and alteration of the nutritional machinery in NSCLC 144
Development of a nomogram for predicting pathological complete response in luminal breast cancer patients following neoadjuvant chemotherapy 141
Combined Large Cell Neuroendocrine Carcinomas of the Lung: Integrative Molecular Analysis Identifies Subtypes with Potential Therapeutic Implications 140
Exercise and anemia in cancer patients: could make the difference? 140
Effect of exercise on functional capacity in patients with advanced cancer: A meta-analysis of randomized controlled trials 140
Predictive and prognostic effect of computed tomography-derived body composition analysis during neoadjuvant chemotherapy for operable and locally advanced breast cancer 139
Molecular predictors of EGFR-mutant NSCLC transformation into LCNEC after frontline osimertinib: digging under the surface 138
Evidence-based tailored nutrition educational intervention improves adherence to dietary guidelines, anthropometric measures and serum metabolic biomarkers in early-stage breast cancer patients: A prospective interventional study 138
Activity of EGFR TKIs in Caucasian Patients With NSCLC Harboring Potentially Sensitive Uncommon EGFR Mutations 137
Platelet-derived growth factor receptor inhibitors for non-small cell lung cancer: is the odyssey over? 136
Impact of exercise in patients with pancreatic cancer across different treatment phases: a systematic review 136
Necitumumab in the treatment of non-small-cell lung cancer: clinical controversies 135
Exercise oncology: It is time to make a change 135
Prognostic Model for Resected Squamous-Cell Lung Cancer: External Multicenter Validation and Propensity Score Analysis exploring the Impact of Adjuvant and Neoadjuvant Treatment 134
Efficacy and safety of afatinib for non-small-cell lung cancer: state-of-the-art and future perspectives 134
PD-L1 for selecting non-small-cell lung cancer patients for first-line immuno-chemotherapy combination: a systematic review and meta-analysis 133
Clinical Features and Progression Pattern of Acquired T790M-positive Compared With T790M-negative EGFR Mutant Non-small-cell Lung Cancer: Catching Tumor and Clinical Heterogeneity Over Time Through Liquid Biopsy 133
Real-world outcomes according to treatment strategies in ALK-rearranged non-small-cell lung cancer (NSCLC) patients: an Italian retrospective study 133
Genetic and non-genetic resistance mechanisms in non-small cell lung cancer harboring (non-ALK) oncogenic fusions 131
Integrating the molecular background of targeted therapy and immunotherapy in lung cancer: a way to explore the impact of mutational landscape on tumor immunogenicity 131
Targeted next-generation sequencing identifies genomic abnormalities potentially driving the prognosis of early-stage invasive lobular breast carcinoma patients stratified according to a validated clinico-pathological model 131
Moving towards a customized approach for drug development: lessons from clinical trials with immune checkpoint inhibitors in lung cancer 131
Exploring the feasibility of a combined exercise program for patients with advanced lung or pancreatic cancer 130
Final data of an Italian multicentric survey about counseling for smoking cessation in patients with diagnosis of a respiratory disease 130
Physical activity and exercise in lung cancer care: will promises be fulfilled? 130
Tracking occult pN2 disease after mediastinal dissection in early stage lung cancer. 130
Feasibility of a novel exercise program for patients with breast cancer offering different modalities and based on patient preference 129
Plasmacytoid Dendritic Cell, Slan+-Monocyte and Natural Killer Cell Counts Function as Blood Cell-Based Biomarkers for Predicting Responses to Immune Checkpoint Inhibitor Monotherapy in Non-Small Cell Lung Cancer Patients 128
Pancreatic Enzyme Replacement Therapy in Patients Undergoing First-Line Gemcitabine Plus nab-paclitaxel for Advanced Pancreatic Adenocarcinoma 126
Prognostic impact of Interleukin-8 levels in lung cancer: A meta-analysis and a bioinformatic validation 126
Implementation outcomes of early nutritional screening and referral for patients with thoracic cancers 126
Avoiding chemotherapy for advanced nononcogene addicted NSCLC overexpressing PD-L1: Rule or option? 126
Genetic, epigenetic and micro-environmental markers as predictors of prognosis, response and resistance to chemotherapy, targeted agents and immunotherapy in resected squamous cell lung carcinoma (SQLC). 124
Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC 124
PTEN in Lung Cancer: Dealing with the Problem, Building on New Knowledge and Turning the Game Around 123
Totale 16.164
Salva come PNG Salva come JPEG
Categoria #
all - tutte 90.916
article - articoli 89.176
book - libri 0
conference - conferenze 1.055
curatela - curatele 0
other - altro 326
patent - brevetti 0
selected - selezionate 0
volume - volumi 359
Totale 181.832
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021193 0 0 0 0 0 0 0 0 0 24 122 47
2021/20221.080 60 292 8 119 39 27 31 58 46 23 95 282
2022/20232.327 144 261 206 411 196 539 19 137 262 21 97 34
2023/20241.661 59 95 158 166 212 267 99 139 39 117 229 81
2024/20254.541 230 184 209 791 148 200 201 192 708 351 435 892
2025/202613.778 848 732 1.103 2.374 3.708 849 1.305 813 1.195 851 0 0
Totale 26.260